Gate2Brain signs Shilpa partnership to advance brain-tumour therapy
The €7 million equity package combines €500,000 in cash, services and project development for a 30.4% stake.
Shilpa Biocare announced a strategic equity partnership with Gate2Brain on June 3, 2026. The agreement gives the pharmaceutical subsidiary a 30.4% stake and a development role in the Barcelona company’s lead brain-cancer programme.
The disclosed €7 million contribution comprises €500,000 in cash, €5.5 million in equity for services and €1 million for project development. The contributions are to be made in tranches under the agreements.
The partners will advance G2B-002 toward human studies by combining Gate2Brain’s peptide-shuttle technology with Shilpa’s manufacturing and regulatory capabilities. G2B-002 remained in preclinical development at the announcement.
Use of funds
Advance G2B-002 toward human studies
Manufacturing and regulatory development